172 related articles for article (PubMed ID: 16095690)
1. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
Perea G; Domingo A; Villamor N; Palacios C; Juncà J; Torres P; Llorente A; Fernández C; Tormo M; Queipo de Llano MP; Bargay J; Gallart M; Florensa L; Vivancos P; Martí JM; Font L; Berlanga J; Esteve J; Bueno J; Ribera JM; Brunet S; Sierra J; Nomdedéu JF;
Leuk Res; 2005 Oct; 29(10):1109-16. PubMed ID: 16095690
[TBL] [Abstract][Full Text] [Related]
2. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic quantitative features of patients with acute myeloid leukemia.
Pereira FG; Metze K; Costa FP; Lima CS; Lorand-Metze I
Neoplasma; 2006; 53(2):155-60. PubMed ID: 16575472
[TBL] [Abstract][Full Text] [Related]
4. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia with pseudo-Chèdiak-Higashi anomaly exhibits a specific immunophenotype with CD2 expression.
Chang H; Yi QL
Am J Clin Pathol; 2006 May; 125(5):791-4. PubMed ID: 16707384
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
7. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
8. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia.
Tamura H; Dan K; Tamada K; Nakamura K; Shioi Y; Hyodo H; Wang SD; Dong H; Chen L; Ogata K
Clin Cancer Res; 2005 Aug; 11(16):5708-17. PubMed ID: 16115907
[TBL] [Abstract][Full Text] [Related]
9. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype.
Chang H; Yeung J; Brandwein J; Yi QL
Leuk Res; 2007 Feb; 31(2):157-62. PubMed ID: 16837044
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
11. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
13. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Paschka P; Marcucci G; Ruppert AS; Mrózek K; Chen H; Kittles RA; Vukosavljevic T; Perrotti D; Vardiman JW; Carroll AJ; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2006 Aug; 24(24):3904-11. PubMed ID: 16921041
[TBL] [Abstract][Full Text] [Related]
14. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia.
Venditti A; Del Poeta G; Maurillo L; Buccisano F; Del Principe MI; Mazzone C; Tamburini A; Cox C; Panetta P; Neri B; Ottaviani L; Amadori S
Haematologica; 2004 Aug; 89(8):934-9. PubMed ID: 15339676
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic impact of karyotype in de novo acute myeloid leukemia: study of 139 cases].
Sennana Sendi H; Elghezal H; Temmi H; Gribaa M; Laatiri A; Ben Abid H; Ben Abdeladhime A; Elloumi M; Hafsia A; Saad A
Tunis Med; 2002 Sep; 80(9):531-5. PubMed ID: 12632766
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of immunophenotype to cytogenetics and clinical features of adult acute myeloid leukemia].
Wang XB; Zheng JE; Gu JX; Yao JX; Yang J; Liu J; Li XQ; He YL; Yu JM; Wei J; Liu ZP; Huang SA
Ai Zheng; 2005 Jun; 24(6):667-71. PubMed ID: 15946475
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
